Dignan,
I stumbled across Transition Therapeutics (Canadian company). They have the following drug/s? in trial. Not sure if it / they are on your list?
Ian
Clinical Development
A Phase II clinical trial is underway in MS patients with data expected in the second half of calendar 2006. A Phase I clinical trial has demonstrated that EMZ701 is well-tolerated and has a good safety profile.
Creating Best-In-Class Multiple Sclerosis Product
Transition is developing MS-I.E.T. (a combination of Transition's interferon enhancer EMZ701 and interferon-beta) which has been shown to improve interferon therapy two to three-fold in MS animal models.